Firmware Supply Chain Company Binarly Raises $3.6 Million from WestWave Capital, Acrobator Ventures
22.6.2022 19:10:00 EEST | Business Wire | Press release
Binarly Inc., a cybersecurity company building technology to address repeatable security failures in the firmware supply chain, today announced $3.6 million in seed funding from WestWave Capital and Acrobator Ventures. Prominent cybersecurity leaders Michael Sutton, Thomas 'Halvar Flake' Dullien, Jamie Butler, Ryan Permeh, Bryson Bort, Pedram Amini, Chris Ueland and David Mandel from Emerging Ventures also joined as investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005392/en/
Founded in 2021, Binarly brings decades of research experience identifying hardware and firmware security weaknesses and threats. Based in Los Angeles, California, Binarly’s agentless, enterprise-class AI-powered firmware security platform helps protect from advanced threats below the operating system. The company’s technology solves firmware supply chain security problems by identifying vulnerabilities, malicious firmware modifications and providing firmware SBOM visibility without access to the source code. Binarly’s cloud-agnostic solutions give enterprise security teams actionable insights, and reduce the cost and time to respond to security incidents. (Graphic: Business Wire)
Binarly is co-founded by security pioneers Alex Matrosov and Claudiu Teodorescu, who previously worked on hardware and software security at NVIDIA, Intel Corp., ESET, BlackBerry, Cylance and FireEye. Matrosov, a highly regarded researcher who is regularly credited with major vulnerability discoveries, is co-author of Rootkits and Bootkits, a seminal book that explains how to understand and counter sophisticated, advanced threats buried deep in a machine’s boot process or UEFI firmware.
Binarly has built a SaaS platform for analyzing, understanding and responding to silent, currently undetectable security threats at the firmware layer. Using a combination of machine learning and deep code inspection at the binary level, Binarly enables security teams to have real visibility into hardware and firmware failures and a simple way to recover from sophisticated attacks below the operating system.
Binarly also developed its own technology for vulnerability management and protecting the firmware supply chain from repeatable failures. The company’s approach uses semantic properties of the binary code to improve detection accuracy by limiting the number of false positives.
So far this year, Binarly has coordinated the disclosure of 107 critical firmware security vulnerabilities affecting the entire enterprise device ecosystem. The company worked with security response teams at Insyde, AMI, Lenovo, Dell, HP, HPE, Siemens, Fujitsu, Atos, Intel, AMD and many other vendors to mitigate high-impact security issues across the computing landscape. Many of these vulnerabilities demonstrate the complexities of the firmware supply chain that negatively disrupt the timeline for patch delivery and identification of impacted parties.
“The current approach in the industry is to detect risks related to the firmware by leveraging the current version number of the firmware update against a public database of vulnerabilities and threats. This leads to firmware supply chain failures because known vulnerabilities that are not associated with a certain version number of a firmware release will not be detected thus keeping the 'doors' open for an attacker,” Matrosov said.
“Assessing the impact of a known firmware based vulnerability in a customer environment, at scale, is a problem without a viable solution. We have developed the FwHunt technology that adds semantic context around a known vulnerability to ensure detection while reducing false positives,” Teodorescu said.
Binarly plans to use the investment to speed up research and development initiatives, expand its world-class engineering team, and scale enterprise and device manufacturer adoption of its technologies.
Quotes from investors:
“We are excited to invest in founders Alex and Claudiu at Binarly. We have immense respect for their deep technical expertise and understanding of the firmware security market. We recognize that there are significant exposure issues in addressing firmware security vulnerabilities and we have strong conviction that Binarly will mitigate those concerns - both immediate and in the long term.” - Warren “Bunny” Weiss, Managing Partner, WestWave Capital.
“CISOs from critical infrastructure companies, hyperscalers, and cybersecurity experts rate firmware security as a top-three priority. In a world where IoT, edge devices and the mere size of firmware on devices significantly increases, it’s a matter of ‘when’ not ‘if’ new dominant security solutions are adopted. Why Binarly? They’ve got the best-in-class team discovering vulnerabilities no one else has found and managed to surround themselves with incredible experts.” - Mike Reiner, General Partner, Acrobator Ventures.
“It’s no secret that firmware security presents a growing challenge that needs to be solved. For far too long, hardware manufacturers have relied on security through obscurity and we’re now paying the price as attackers identify and exploit flaws that impact thousands of devices across the globe. Blindly trusting hardware manufacturers is a recipe for disaster. The Binarly team has the expertise and vision to finally execute on delivering a scalable solution to get this problem under control.” - Michael Sutton, Managing Partner, Stonemill Ventures.
About WestWave Capital:
WestWave Capital is an early-stage Venture Capital firm that invests in Seed and Series A Enterprise companies building deep technology solutions. The company’s investments focus on SaaS, Security, Cloud Infrastructure, Blockchain, Analytics, and IoT companies.
About Acrobator Ventures:
Acrobator Ventures is an operator-led venture capital fund focused on early stage tech in the Benelux & CIS operating out of Kiev and Amsterdam.
About Binarly:
Founded in 2021, Binarly brings decades of research experience identifying hardware and firmware security weaknesses and threats. Based in Los Angeles, California, Binarly’s agentless, enterprise-class AI-powered firmware security platform helps protect from advanced threats below the operating system. The company’s technology solves firmware supply chain security problems by identifying vulnerabilities, malicious firmware modifications and providing firmware SBOM visibility without access to the source code. Binarly’s cloud-agnostic solutions give enterprise security teams actionable insights, and reduce the cost and time to respond to security incidents.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220622005392/en/
Contact information
Alex Matrosov
media@binarly.io
818.351.9637
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
